Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Radiation-induced skin injury: a review of pathophysiology, assessment, management, and re-irradiation protocols

Cheng J., Dong J., Fang Y., Zhang X., Dang X.

Narrative Review, published in Front Oncol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Oncol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41669267
PMCID
PMC12883423
DOI
10.3389/fonc.2025.1736717
Citations
1

Abstract (original English)

Background Radiation-induced skin injury (RISI) is a common dose-limiting toxicity of radiotherapy, characterized by erythema, desquamation, fibrosis, atrophy, and ulceration. It results from DNA damage, reactive oxygen species, and dysregulated inflammation. Purpose This review synthesizes current knowledge on the mechanisms, assessment tools, and management strategies of RISI, with a focus on emerging therapeutic approaches, particularly in patients requiring re-irradiation. Materials and methods A search of PubMed, Embase, and Web of Science for English-language studies from 2020 to 2025 using terms like "radiation dermatitis," "skin toxicity," and "stem cell therapy" identified 122 pre-clinical and clinical studies. Results Key grading tools for RISI include the Radiation Therapy Oncology Group (RTOG), Common Terminology Criteria for Adverse Events (CTCAE), and Radiation-Induced Skin Reaction Assessment Scale (RISRAS). Conventional treatments like corticosteroids and emollients alleviate symptoms but do not prevent chronic damage. Novel therapies, including mesenchymal stem cells and mitochondrial-targeted antioxidants, show promise in reducing dermal injury and enhancing repair. Re-irradiated patients experience increased severe dermatitis, highlighting the need for better dose-to-skin constraints. Conclusion While current management remains mostly palliative, emerging the

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.